Olorofim is under clinical development by F2G and currently in Pre-Registration for Fungal Infections. According to GlobalData, Pre-Registration drugs for Fungal Infections have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Olorofim’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Olorofim overview

Olorofim (F-901318) is under development for the treatment of invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis, and coccidioidomycosis. The drug candidate is formulated as tablet and administered through oral route and also administered through intravenous route. The drug candidate belongs to the orotomide class which acts by targeting dihydroorotate dehydrogenase (DHODH). The drug candidate is developed based on MycoBank technology. It was also under development for the treatment of aspergillosis as the intravenous formulation.

F2G overview

F2G, formerly Functional Fungal Genomics, is a biopharmaceutical company that focuses on discovery and development of orotomides to treat fungal infections. It is investigating its lead compound Olorofim, an antifungal agent for the treatment of invasive aspergillosis, coccidioidomycosis, scedosporiosis, and other invasive mold infections. The company is also evaluating intravenous (IV) inhaled formulations against chronic pulmonary mold infections including pulmonary aspergillosis. F2G’s product candidate targets fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. It has operational presence in New Jersey, the US; and Vienna, Austria. F2G is headquartered in Eccles, Manchester, the UK.

For a complete picture of Olorofim’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.